BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/19/2024 10:24:53 AM | Browse: 189 | Download: 604
 |
Received |
|
2024-01-29 15:17 |
|
Peer-Review Started |
|
2024-01-29 15:18 |
|
First Decision by Editorial Office Director |
|
2024-02-20 01:38 |
|
Return for Revision |
|
2024-02-20 01:38 |
|
Revised |
|
2024-02-21 22:59 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-03-20 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-03-20 06:19 |
|
Articles in Press |
|
2024-03-20 06:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-30 23:02 |
|
Publish the Manuscript Online |
|
2024-06-19 10:24 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Eribulin in breast cancer: Current insights and therapeutic perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Oliver Oey, Wynne Wijaya and Andrew Redfern |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wynne Wijaya, MD, Master's Student, Research Assistant, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom. wynne.wijaya@oncology.ox.ac.uk |
| Key Words |
Eribulin; Breast cancer; Metastatic breast cancer; Chemotherapy; Efficacy; Safety |
| Core Tip |
Eribulin is a non-taxane chemotherapeutic agent which is utilised for the treatment of locally advanced or metastatic breast cancer patients who have progressed after 2-3 lines of taxane or anthracycline-based regimen. Eribulin’s non-mitotic properties which include its anti-mesenchymal, immunomodulating and vascular remodelling features could make it a perfect candidate in becoming adjuncts to standard treatment regimen for breast cancer across different subtypes. In the era of targeted therapy, immunotherapy and antibody-drug conjugates, we review current evidence to elucidate whether eribulin still has a role to play in earlier and later-line settings both as a single agent and in combination with other agents in patients with metastatic breast cancer across all subtypes of breast cancer. |
| Publish Date |
2024-06-19 10:24 |
| Citation |
Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. World J Exp Med 2024; 14(2): 92558 |
| URL |
https://www.wjgnet.com/2220-315x/full/v14/i2/92558.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v14.i2.92558 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
